Health Care • Biotechnology: Laboratory Analytical Instruments
$372.18 ▼ -12.22
(-3.18%)
MKT CAP: $10.28B • VOL: 183.1K
52W L $237 52W H $396
BIO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.58B | $2.57B | $2.67B |
| YoY Revenue Growth % | +0.7% | -3.9% | — |
| Gross Profit | $1.34B | $1.38B | — |
| Gross Margin % | 51.9% | 53.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $47.2M | $269.0M | $337.8M |
| Operating Margin % | 1.8% | 10.5% | 12.6% |
| Net Income (GAAP) | $759.9M | -$1.84B | -$637.3M |
| EBITDA (Normalized) | $173.3M | $401.5M | $434.0M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $532.2M | $455.2M | $374.9M |
| Capital Expenditures (CapEx) | $157.6M | $165.6M | $120.2M |
| Free Cash Flow (FCF) | $374.6M | $289.6M | $254.7M |
| FCF Margin % | 14.5% | 11.3% | 9.5% |
| Return on Invested Capital (ROIC %) | 0.5% | 2.9% | 7.8% |
| Cash & Short-Term Equivalents | $529.8M | $488.1M | — |
| Total Debt (Short + Long Term) | $1.20B | $1.20B | $1.32B |
| Total Stockholders' Equity | $7.45B | $6.57B | $2.71B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BIO.